Author:
Bussing David,Sharma Sharad,Li Zhe,Meyer Lyndsey F.,Shah Dhaval K.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. Lancet. 2019;394(10200):793–804.
2. Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired resistance to antibody-drug conjugates. Cancers (Basel). 2019;11(3).
3. Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19(2):79–84.
4. FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies [press release]. U.S. Food and Drug Administration, December 20, 2019.
5. FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments [press release]. U.S. Food and Drug Administration, April 22, 2020.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献